- Home
- RPHM
as 07-26-2024 4:00pm EST
Reneo Pharmaceuticals Inc is a clinical-stage pharmaceutical company. It is focused on the development of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The company is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | IRVINE |
| Market Cap: | 50.1M | IPO Year: | 2021 |
| Target Price: | $8.58 | AVG Volume (30 days): | 166.3K |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.18 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.98 - $9.21 | Next Earning Date: | 08-08-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Reneo Pharmaceuticals Inc. (RPHM)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Leonard Braden Michael | RPHM | 10% Owner | May 14 '24 | Buy | $1.56 | 79,281 | $123,678.36 | 2,337,194 | SEC Form 4 |
| Leonard Braden Michael | RPHM | 10% Owner | May 14 '24 | Buy | $1.54 | 335,000 | $515,900.00 | 2,672,194 | SEC Form 4 |
Latest Reneo Pharmaceuticals Inc. News
RPHM Breaking Stock News: Dive into RPHM Ticker-Specific Updates for Smart Investing
PR Newswire
2 months ago
Getting smarter: FIA Launches 3-Day Smart Driving Challenge in Samarkand, Powered by Greater Than
PR Newswire
2 months ago
3 Major Product Releases at 3Shape Discover Event
Business Wire
2 months ago
Net Asset Value(s)
AFP
2 months ago
Irish, Czechs hold EU vote after Dutch far-right gains
Motley Fool
2 months ago
Trade the Nvidia Stock Split? The Tried-and-True Method to Make the Best Profits on the Leading AI Stock
GlobeNewswire
2 months ago
GPRC5D Targeting Drugs Market Opportunity and Clinical Trials Insight 2024: Insight on 15+ Drugs in Clinical Trials
![[Latest] Global Virtual Reality In Gaming Market Size/Share Worth USD 103,244.7 Million by 2033 at a 16.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)](https://cdn.finquota.com/news/110846e4-5b88-4e9a-b833-3a7f56abaaa8.png)
GlobeNewswire
2 months ago
[Latest] Global Virtual Reality In Gaming Market Size/Share Worth USD 103,244.7 Million by 2033 at a 16.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
PR Newswire
2 months ago
Bitcoin ReoPro 3.0 Transforms Trading with AI Innovation
Compare RPHM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RPHM Reneo Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.